<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151315">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01863589</url>
  </required_header>
  <id_info>
    <org_study_id>112299</org_study_id>
    <nct_id>NCT01863589</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation for HEPSERA (Adefovir) Tablet</brief_title>
  <official_title>Drug Use Investigation for HEPSERA (Adefovir) Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data
      among subjects with chronic hepatitis B and hepatic cirrhosis B who is treated with adefovir
      tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The incidence of adverse drug reactions</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">436</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Subjects prescribed adefovir tablets</arm_group_label>
    <description>Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir tablets</intervention_name>
    <description>Administered according to the prescribing information in the locally approved label by the authorities.</description>
    <arm_group_label>Subjects prescribed adefovir tablets</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with chronic hepatitis B or hepatic cirrhosis B who are confirmed of hepatic
        function abnormality with continuous re-proliferation of hepatitis B virus while treated
        with lamivudine
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with chronic hepatitis B or hepatic cirrhosis B

          -  Subjects treated with adefovir tablets

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 23, 2013</lastchanged_date>
  <firstreceived_date>October 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
